Incyte is trading at $118.00, up 4.18% in pre-market; no verified company-specific announcement on October 16 clearly explains the move. - FDA approval of Atebrioz was announced September 25 and is not a fresh catalyst. - Recent analyst actions were mixed: Canaccord reiterated Buy, while Wells Fargo maintained Hold; available coverage does not establish these actions as the cause of the gain. - Broader index futures were mixed, with no strong same-direction market move indicated.